with an incremental cost-effectiveness ratio (ICER) below £30,000 per QALY.
NICE guidance on everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease was published in June 2017. This recommends everolimus and sunitinib as options for treating well- or moderately differentiated unresectable or metastatic neuroendocrine tumours (NETs) of pancreatic origin in adults with progressive disease. In addition everolimus is recommended as an option for treating well-differentiated (grade 1 or grade 2) non-functional unresectable or metastatic NETs of gastrointestinal or lung origin in adults with progressive disease. Everolimus is recommended only when the company provides it with the discount agreed in the patient access scheme.